Andreas Tiede on Antithrombotic Drugs and Their Role in Cancer Progression and Metastasis
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post by NEJM Group on LinkedIn, adding:
“I wouldn’t treat cancer patients with aspirin — yet —, but it is worthwhile observing the field of antithrombotic drugs affecting cancer progression and metastasis. Anticoagulants like heparin were sometimes reported to have similar effects.”
Quoting NEJM Group‘s post:
“A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.
The effects of aspirin on cancer metastasis were first recognized more than 50 years ago. In a seminal study, Gasic and colleagues found that fewer lung metastases developed in mice whose drinking water was supplemented with aspirin than in control mice.
Epidemiologic data support the hypothesis that aspirin prevents cancer, but the design and interpretation of randomized trials have been hampered by a lack of mechanistic understanding.
This is changing. In a recent report, Yang and colleagues describe a previously unrecognized immunosuppressive mechanism that prevents T cells from eliminating cancer metastases.
At the heart of this prometastatic mechanism is a protein called ARHGEF1, which is activated by thromboxane A2 (TXA2), a metabolite of the platelet arachidonic acid pathway. This pathway is inhibited by aspirin through inactivation of cyclooxygenase (COX) enzymes.
Title: Understanding How Aspirin Prevents Metastasis
Authors: Ruth E. Langley, John Burn
Read the full article on the NEJM.
Read also on Hemostasis Today: Eric Topol on How Low-Dose Aspirin May Help Prevent Cancer Metastasis
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers